Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612270 | 0.89 | KCNH2 (0.49) | KCNH2CYP3A4CYP2D6CYP2C9IDO1 | |
| SCHEMBL3151001 | 0.87 | KCNH2 (0.45) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL30601611 | 0.87 | KCNH2 (0.45) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL3159602 | 0.81 | CYP3A4 (0.49) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL3151052 | 0.81 | CYP3A4 (0.55) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL13119805 | 0.81 | KCNH2 (0.48) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL13690733 | 0.79 | CYP3A4 (0.43) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL3145181 | 0.78 | CYP3A4 (0.43) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 | |
| SCHEMBL3152053 | 0.78 | CYP3A4 (0.42) | KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13690909 | 0.77 | KCNH2 (0.43) | KCNH2CYP3A4CYP2D6CYP2C9CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | claimed |
| EP-1912935-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9487476-B2 | Catechol diethers as potent anti-HIV agents | YALE UNIVERSITY (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487476-B2 | Catechol diethers as potent anti-HIV agents | YALE UNIVERSITY (US) | 2016-11-08 | — | — | US | disclosed |
| US-20140288017-A1 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-25 | — | — | US | disclosed |
| US-20140288017-A1 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-25 | — | — | US | disclosed |
| WO-2013056003-A2 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | YALE UNIVERSITY (US) | 2013-04-18 | — | — | WO | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1912935-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288017-A1 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS | COMT, NNMT, PNMT | KCNH2 4789/4885CYP3A4 827/4885CYP2D6 456/4885 |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | KCNH2 3118/4885CYP3A4 862/4885CYP2D6 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.